Previous Close | 27.44 |
YTD Return | N/A |
Expense Ratio (net) | N/A |
Category | N/A |
Last Cap Gain | N/A |
Morningstar Rating | N/A |
Morningstar Risk Rating | N/A |
Sustainability Rating | N/A |
Net Assets | N/A |
Beta (5Y Monthly) | N/A |
Yield | N/A |
5y Average Return | N/A |
Holdings Turnover | N/A |
Last Dividend | N/A |
Average for Category | N/A |
Inception Date | N/A |
Moderna CEO Stéphane Bancel joins Yahoo Finance Live to discuss fourth quarter earnings for the company, global COVID-19 vaccine equity, and the outlook for production amid Russia-Ukraine tensions.
Announcement follows CHMP's previous decision to adopt a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include adolescents 12 years of age and older.CAMBRIDGE, MA / ACCESSWIRE / February 24, 2022 / Moderna, Inc.
Oppenheimer Analyst Hartaj Singh joins Yahoo Finance Live to discuss fourth quarter earnings for Moderna.